Results

571 - 580 of 583 results for ‘See colaplug.com for buy mdma online’.

  • 22. Tetanus

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/22-tetanus

    Key information Mode of transmission Environmental exposure to the bacillus, usually through contaminated wounds. The disease is not directly transmitted from person to person. Incubation period Between 3 and 21 days, commonly about 10 days; may vary from 1 day to several months. Period of communicability A person with tetanus is not infectious to others. Incidence and burden of disease Older individuals, usually women, who are less likely to have received a primary series of tetanus vaccine; and in unvaccinated children. Funded vaccines DTaP-IPV-HepB/Hib (Infanrix-hexa). DTaP-IPV (Infanr ...

  • 15. Mumps

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/15-mumps

    Key information Mode of transmission Airborne droplets or by direct contact with saliva or urine from an infected person. Incubation period About 16 to 18 days, ranging from 12 to 25 days. Period of communicability For contact tracing purposes, the recommended period of communicability is from 2 days before to 5 days after the onset of parotitis. The virus is also transmitted by asymptomatic infections. Incidence and burden of disease Outbreaks are continuing to occur in New Zealand. Funded vaccine MMR (Priorix) is a live attenuated vaccine. Dose, presentation, route 0.5 mL per dose after reco ...

  • 24. Varicella (chickenpox)

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/24-varicella-chickenpox

    Key information Mode of transmission Airborne droplets from, or contact with, vesicular lesions or possibly respiratory secretions. Incubation period Usually 14–16 days (range 10–21 days). Period of communicability From 2 days before onset of the rash until all lesions have crusted. Incidence and burden of disease Without immunisation, most people have infection during childhood. Groups at risk of severe complications include pregnant women and their unborn babies, and immunocompromised individuals. Funded vaccine VV (Varilrix) is a live attenuated vaccine. Dose, presentation, route 0.5 mL ...

  • 7. Haemophilus influenzae type b (Hib) disease

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/7-haemophilus-inuenzae-type-b-hib-disease

    Key information Mode of transmission By inhalation of respiratory tract droplets or by direct contact with respiratory tract secretions. Incubation period Unknown, but probably 2–4 days. Period of communicability May be prolonged. Non-communicable within 24–48 hours after starting effective antimicrobial therapy. Burden of disease Children aged under 5 years, particularly those aged under 1 year: meningitis, epiglottitis, pneumonia and bacteraemia. Funded vaccines DTaP-IPV-HepB/Hib (Infanrix-hexa). Hib-PRP (Act-HIB). Dose, presentation, route DTaP-IPV-HepB/Hib and Hib-PRP: 0.5 mL per dose ...

  • 9. Hepatitis B

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/9-hepatitis-b

    Key information Mode of transmission Contact with infected blood or body fluids during childbirth (vertical transmission); sexual intercourse, intravenous drug use or contact with broken skin (horizontal transmission). Incubation period 45–180 days, commonly 60–90 days. Period of communicability Potentially infectious 2–3 weeks before the onset of symptoms, during the clinical disease and usually for 2–3 months after acute hepatitis B illness; or for as long as HBsAg continues to be present in blood (chronic hepatitis B carrier state). Incidence and burden of disease New Zealand is a ...

  • Acute rheumatic fever

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/communicable-disease-control-manual/acute-rheumatic-fever

    Summary of updates to the guidance Expand all 2025   2025   April  Full chapter update to new format following a significant update to the 2024 Acute Rheumatic Fever Guidelines. Includes changes to the following sections:   Epidemiology – new section At risk and priority populations – new section  The disease – new section   Updated detail on the role of Group A Strep in diagnosis.  Spread of infection – new section   Routine prevention – new section   New overview on primordial, primary and secondary disease prevention.  Case def ...

  • Health Information Standards Organisation (HISO)

    http://corporat-prod.sites.silverstripe.com/health-services-and-programmes/digital-health/data-and-digital-standards/health-information-standards-organisation-hiso

    How we operate Our standards team works with the appointed HISO sector committee to oversee the selection, development and adoption of data and digital standards for the health sector. Working with subject matter experts and stakeholders, we determine the standards that are to have national effect and manage their rollout. This is achieved by working with partner agencies, health providers, Hauora Māori groups, clinical and consumer groups, the health software industry, overseas jurisdictions and international organisations. Our work improving the interoperability of data and digital systems ...

  • 14. Mpox (orthopoxvirus)

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/14-mpox

    Key information Mode of transmission Close physical contact, including intimate household and sexual contact, with bodily fluids or internal mucosal surfaces, direct contact with skin lesions and contaminated objects, such as bedding, or prolonged exposure to respiratory droplets Incubation period Average 6 to 13 days, range of 2 to 21 days. Period of communicability Self-limiting, usually 2 to 4 weeks.  Funded and available vaccine Mpox (orthopoxvirus) vaccine (MPV): Jynneos (Bavarian Nordic) Live non-replicating vaccine Dose, presentation, route 0.5 mL per dose, two doses given at least ...

  • 6. Diphtheria

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/6-diphtheria

    Key information Mode of transmission Contact with respiratory droplets or infected skin of a case or carrier or, more rarely, contaminated objects. Incubation period Usually 2–5 days, occasionally longer. Period of communicability Variable; usually 2 weeks or less, seldom more than 4 weeks. Carriers may shed for longer. Effective antimicrobial therapy promptly terminates shedding. Funded and available vaccines DTaP-IPV-HepB/Hib (Infanrix-hexa). DTaP-IPV (Infanrix-IPV). Tdap (Boostrix). Dose, presentation, route 0.5 mL per dose. DTaP-IPV-HepB/Hib: pre-filled syringe and glass vial. The vaccin ...

  • 25. Zoster (herpes zoster/shingles)

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/25-zoster-herpes-zostershingles

    Key information Mode of transmission Zoster is a reactivation of the varicella-zoster virus in someone who has previously had varicella disease (most often as chickenpox). Direct contact with zoster vesicles has a low risk of causing varicella in non-immune individuals – can be prevented by covering the rash. There is potential for aerosol transmission from some immunocompromised cases with viraemia. Period of communicability Until lesions have crusted. Incidence and burden of disease Increasing incidence with age; lifetime risk about 1 in 3. For those aged over 85 years, the risk is 1 in 2. ...